AETHLON MEDICAL INC (Nasdaq:AEMD)
Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. It develops Aethlon Hemopurifier, which is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The firm operates through the following segments: Aethlon and ESI. The Aethlon segment is involved in therapeutic business activities. The ESI segment consists of diagnostic business activities. The company was founded by James A. Joyce in 1991 and is headquartered in San Diego, CA.
11555 Sorrento Valley Road
Suite 203
San Diego, California 92121
14
$0.4880
0.4450 - 0.4880
0.2375 - 1.8500
3.16M
998.09K (02/14/25)
7.06%
$7.06M
N/A
-$12.21M
N/A
CEO, Chief Financial Officer, Secretary & Director James B. Frakes |
Independent Chairman Edward G. Broenniman |
Independent Director Angela Rossetti |
Independent Director Nicolas Gikakis |
Independent Director Chetan S. Shah |
Date | Form | Event |
---|---|---|
20 Dec, 2024 | 8-K | |
15 Nov, 2024 | S-8 | |
13 Nov, 2024 | 8-K | |
13 Nov, 2024 | 10-Q | |
12 Nov, 2024 | 8-K | |
3 Oct, 2024 | 8-K | |
2 Oct, 2024 | 8-K | |
1 Oct, 2024 | 4 | |
1 Oct, 2024 | 4 | |
1 Oct, 2024 | 4 | |
19 Sep, 2024 | 8-K | |
15 Aug, 2024 | ARS | |
15 Aug, 2024 | DEFA14A | |
15 Aug, 2024 | DEF 14A | |
15 Aug, 2024 | 10-K/A | |
14 Aug, 2024 | 10-Q | |
14 Aug, 2024 | 8-K | |
12 Aug, 2024 | 8-K | |
3 Jul, 2024 | 8-K | |
1 Jul, 2024 | 4 | |
1 Jul, 2024 | 4 | |
1 Jul, 2024 | 4 | |
27 Jun, 2024 | 10-K | |
27 Jun, 2024 | 8-K | |
24 May, 2024 | 8-K | |
17 May, 2024 | 8-K | |
16 May, 2024 | 424B4 | |
16 May, 2024 | EFFECT | |
15 May, 2024 | POS AM | |
15 May, 2024 | EFFECT | |
13 May, 2024 | S-1/A | |
10 May, 2024 | CORRESP | |
10 May, 2024 | 8-K | |
10 May, 2024 | CORRESP | |
25 Apr, 2024 | 8-K | |
25 Apr, 2024 | S-1/A | |
17 Apr, 2024 | 4 | |
17 Apr, 2024 | 4 | |
17 Apr, 2024 | 4 | |
17 Apr, 2024 | 4 | |
5 Apr, 2024 | S-1/A | |
1 Apr, 2024 | 4 | |
1 Apr, 2024 | 4 | |
1 Apr, 2024 | 4 | |
28 Mar, 2024 | UPLOAD | |
22 Mar, 2024 | S-1 | |
14 Feb, 2024 | 8-K | |
14 Feb, 2024 | 10-Q | |
2 Jan, 2024 | 4 | |
2 Jan, 2024 | 4 | |
2 Jan, 2024 | 4 | |
22 Dec, 2023 | 8-K/A | |
27 Nov, 2023 | 8-K | CEO Change |
14 Nov, 2023 | 10-Q | |
14 Nov, 2023 | 8-K | |
13 Nov, 2023 | 8-K | CEO Change |
4 Oct, 2023 | 8-K | |
29 Sep, 2023 | 4 | |
29 Sep, 2023 | 4 | |
29 Sep, 2023 | 4 | |
18 Sep, 2023 | 8-K | |
10 Aug, 2023 | 10-Q | |
10 Aug, 2023 | 8-K | |
27 Jul, 2023 | DEF 14A | |
27 Jul, 2023 | ARS | |
17 Jul, 2023 | PRE 14A | |
6 Jul, 2023 | 4 | |
6 Jul, 2023 | 3 | |
6 Jul, 2023 | 8-K | |
3 Jul, 2023 | 4 | |
3 Jul, 2023 | 4 | |
28 Jun, 2023 | 10-K | |
28 Jun, 2023 | 8-K | |
1 May, 2023 | 4 | |
1 May, 2023 | 4 | |
1 May, 2023 | 4 | |
25 Apr, 2023 | 8-K | |
31 Mar, 2023 | 4 | |
31 Mar, 2023 | 4 | |
13 Feb, 2023 | 8-K | |
13 Feb, 2023 | 10-Q | |
2 Feb, 2023 | 4 | |
2 Feb, 2023 | 3 | |
30 Dec, 2022 | 4 | |
30 Dec, 2022 | 4 | |
14 Nov, 2022 | 10-Q | |
14 Nov, 2022 | 8-K | |
27 Oct, 2022 | 8-K | |
4 Oct, 2022 | 4 | |
4 Oct, 2022 | 4 | |
29 Sep, 2022 | 8-K | |
29 Sep, 2022 | 424B5 | |
29 Sep, 2022 | 8-K | |
19 Sep, 2022 | 8-K | |
19 Sep, 2022 | S-8 | |
16 Sep, 2022 | 4 | |
16 Sep, 2022 | 4 | |
16 Sep, 2022 | 4 | |
9 Aug, 2022 | 10-Q | |
9 Aug, 2022 | 8-K | |
3 Aug, 2022 | 424B5 | |
27 Jul, 2022 | DEF 14A | |
15 Jul, 2022 | PRE 14A | |
28 Jun, 2022 | 8-K | |
28 Jun, 2022 | 10-K | |
1 Apr, 2022 | 3 | |
31 Mar, 2022 | 4 | |
31 Mar, 2022 | 4 | |
31 Mar, 2022 | 4 | |
28 Mar, 2022 | 8-K | |
24 Mar, 2022 | 8-K | |
24 Mar, 2022 | 424B5 | |
14 Feb, 2022 | 10-Q | |
14 Feb, 2022 | 8-K | |
11 Feb, 2022 | 4 | |
11 Feb, 2022 | 4 | |
11 Feb, 2022 | 4 | |
11 Feb, 2022 | 4 | |
13 Jan, 2022 | SC 13G/A | |
3 Jan, 2022 | 4 | |
3 Jan, 2022 | 4 | |
3 Jan, 2022 | 4 | |
9 Nov, 2021 | 8-K | |
9 Nov, 2021 | 10-Q | |
1 Nov, 2021 | 8-K | |
21 Oct, 2021 | EFFECT | |
1 Oct, 2021 | 4 | |
1 Oct, 2021 | 4 | |
1 Oct, 2021 | 4 | |
30 Sep, 2021 | S-3 | |
17 Sep, 2021 | 8-K | |
9 Aug, 2021 | 10-Q | |
9 Aug, 2021 | 8-K | |
28 Jul, 2021 | DEFA14A | |
28 Jul, 2021 | DEF 14A | |
1 Jul, 2021 | 4 | |
1 Jul, 2021 | 8-K | |
1 Jul, 2021 | 4 | |
1 Jul, 2021 | 4 | |
30 Jun, 2021 | 4 | |
24 Jun, 2021 | 10-K | |
24 Jun, 2021 | 8-K | |
15 Jun, 2021 | SC 13G | |
11 Jun, 2021 | 8-K | |
11 Jun, 2021 | 424B5 | |
2 Apr, 2021 | 4 | |
2 Apr, 2021 | 4 | |
2 Apr, 2021 | 4 | |
2 Apr, 2021 | 4 | |
2 Apr, 2021 | 4 | |
22 Mar, 2021 | 424B5 | |
22 Mar, 2021 | 8-K | |
22 Feb, 2021 | SC 13G/A | |
10 Feb, 2021 | 8-K | |
10 Feb, 2021 | 10-Q | |
29 Jan, 2021 | SC 13G/A | |
13 Jan, 2021 | SC 13G | |
11 Jan, 2021 | 8-K | |
7 Jan, 2021 | 4 | |
7 Jan, 2021 | 3 | |
6 Jan, 2021 | 4 | |
4 Jan, 2021 | 4 | |
4 Jan, 2021 | 4 | |
4 Jan, 2021 | 4 | |
4 Jan, 2021 | 4 | |
4 Jan, 2021 | 4 |
Sign Up to Subscribe
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.